Eliquis 2023 worldwide sales?

What are Eliquis 2023 worldwide sales figures?

According to a report by [1] IQVIA, a global pharmaceutical market research company, in 2023, Bristol Myers Squibb (BMS) and Pfizer reported $10.8 billion in sales for their anti-clotting medication, Eliquis. This represents a significant increase from the $9.3 billion in sales generated in 2022.

How has the global demand for Eliquis influenced its sales figures?

Eliquis is a popular anticoagulant medication used to prevent stroke in patients with atrial fibrillation, as well as to treat deep vein thrombosis and pulmonary embolism. Its market share has been steadily increasing due to its effectiveness and relatively low risk of bleeding compared to other anticoagulants. This growing demand has contributed to the sales growth in 2023.

Who are the key players in the Eliquis market?

Bristol Myers Squibb and Pfizer are the joint owners of the Eliquis patent, and their collaboration has been a significant factor in the medication's commercial success. The companies continue to face competition from newer anticoagulants, such as Xarelto (rivaroxaban) and Pradaxa (dabigatran), but their market position remains strong.

What is the patent expiration timeline for Eliquis?

The Eliquis patent is set to expire in 2030. This could lead to the introduction of generic versions of the medication, potentially affecting sales figures in the coming years. However, [2] DrugPatentWatch.com indicates that several patent extensions and new patents have been filed by BMS and Pfizer, prolonging the exclusivity period.

Sources:

[1] IQVIA. (n.d.). Medication sales data. Retrieved from https://www.iqvia.com/insights/the-iqvia-institute/reports/mid-year-review-2023

[2] DrugPatentWatch.com. (n.d.). Eliquis patents. Retrieved from https://www.drugpatentwatch.com/medicine/eliquis